Filtered By:
Condition: Heart Failure
Education: Study
Procedure: Transplants
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 223 results found since Jan 2013.
Cerebrovascular Accidents During Mechanical Circulatory Support Clinical Sciences
Conclusions—Stroke is a major cause of morbidity and mortality in patients on LVAD support. Chronic obstructive pulmonary disease increases the risk of ischemic stroke, whereas dialysis may increase the risk of hemorrhagic stroke. Although any stroke increases mortality, post-LVAD hemorrhagic stroke was associated with higher mortality compared with ischemic stroke.
Source: Stroke - April 23, 2018 Category: Neurology Authors: Saef Izzy, Daniel B. Rubin, Firas S. Ahmed, Feras Akbik, Simone Renault, Katelyn W. Sylvester, Henrikas Vaitkevicius, Jennifer A. Smallwood, Michael M. Givertz, Steven K. Feske Tags: Heart Failure, Complications, Quality and Outcomes, Intracranial Hemorrhage, Ischemic Stroke Original Contributions Source Type: research
Stroke versus non-stroke neurological complications after cardiac transplant (P4.299)
Conclusions:Neurological complications after CT in our population reach nearly a quarter of patients, similar to or even lower than in previous studies.4.3% of patients developed stroke, ischemic subtype.Pre- and perioperative variables do not differ between both groups, except from ischemic cardiomyopathy as the cause of heart failure being it more frequent in the stroke group.Disclosure: Dr. Vazquez has nothing to disclose. Dr. Thomson has nothing to disclose. Dr. Molina Melendres has nothing to disclose. Dr. Nadile has nothing to disclose. Dr. Gonzalez Toledo has nothing to disclose. Dr. Claverie has nothing to disclose...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Vazquez, G., Thomson, A., Melendres, J. M., Nadile, D., Toledo, M. E. G., Claverie, C. S., Thomson, A., Peradejordi, M., Couto, B., Favaloro, L. E., Favaloro, R., Bertolotti, A., Klein, F. Tags: In-Hospital Stroke Care Source Type: research
Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research
Conclusion
The high prevalence of comorbidities in patients with stroke indicates the need for therapies in preclinical studies that take into account these comorbidities in order to avoid failures in translation to the patient. Preclinical studies are beginning to evaluate the efficacy of MSC treatment in stroke associated with comorbidities, especially hypertension, for ischemic and hemorrhagic stroke. Regarding aging and diabetes, only ischemic stroke studies have been performed. For the moment, few studies have been performed and contradictory results are being reported. These contradictory results may be due to the u...
Source: Frontiers in Neurology - April 8, 2019 Category: Neurology Source Type: research
Medtronic touts stroke data for HeartWare LVAD
A retrospective analysis of two studies involved the HeartWare left-ventricular assist device Medtronic (NYSE:MDT) acquired in 2016 showed that managing blood pressure reduced the severity of strokes in patients implanted with the HVAD pump.
The analysis, of “destination therapy” patients who are not candidates for a heart transplant, took data from the Endurance and Endurance Supplemental studies. Results were presented this week at the annual meeting of the International Society for Heart & Lung Transplantation in London, Medtronic said.
The 465-patient Endurance Supplemental study compared 308 patients i...
Source: Mass Device - April 5, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Assist Devices Clinical Trials Featured Abbott HeartWare International Inc. Medtronic stjudemedical Thoratec Corp. Source Type: news
Stroke After Left Ventricular Assist Device Implantation: Outcomes in the Continuous-Flow Era.
CONCLUSIONS: Stroke while on CF-LVAD support was associated with significant mortality. To reduce the risk of stroke, it is essential to further elucidate risk factors, to optimize anticoagulation, and to further understand the impact of LVAD-related infections.
PMID: 26070599 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - June 9, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Harvey L, Holley C, Roy SS, Eckman P, Cogswell R, Liao K, John R Tags: Ann Thorac Surg Source Type: research
Systemic Inflammation Exacerbates Stroke in Patients with Left Ventricular Assist Device (P4.235)
CONCLUSIONS:In LVAD patients, total prevention of cerebrovascular complications cannot be accomplished only by adjusting warfarin dosage to meet the therapeutic range. However, recognition of increased CRP and appropriate management of inflammation prior to the stroke onset may enable us to avoid its aggravation and secure patient’s opportunity for heart transplantation.Disclosure: Dr. Ohtomo has nothing to disclose. Dr. Iwata has received personal compensation for activities with Janssen Pharmaceuticals, Eisai Inc., Daiichi Pharmaceutical Corp., Ono Pharmaceutical, and Takeda Pharmaceutical Co. Ltd. Dr. Iwata has re...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ohtomo, R., Iwata, A., Kinoshita, O., Shimizu, J., Ono, M., Tsuji, S. Tags: Cerebrovascular Disease and Interventional Neurology: Cardiac Source Type: research
Stroke After Left Ventricular Assist Device Implantation: Outcomes in the Continuous-Flow Era
Conclusions Stroke while on CF-LVAD support was associated with significant mortality. To reduce the risk of stroke, it is essential to further elucidate risk factors, to optimize anticoagulation, and to further understand the impact of LVAD-related infections.
Source: The Annals of Thoracic Surgery - June 10, 2015 Category: Cardiovascular & Thoracic Surgery Source Type: research
ISHLT 2017: Medtronic HVAD trial misses primary endpoint, reports lowered stroke rates
Medtronic (NYSE:MDT) said today that results from the Endurance supplemental trial of its HVAD heart pump system did not meet its primary endpoint, but did report lowered stroke rates compared to standard treatment.
The trial aimed to evaluate the use of the HVAD system, which it picked up along with HeartWare last year, as a destination therapy for patients who require a left ventricular assist device and received improved blood pressure management, the Fridley, Minn.-based company said.
Data from the study was presented at the 2017 International Society for Heart and Lung Transplantation Scientific Meeting in San Dieg...
Source: Mass Device - April 5, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Assist Devices Cardiovascular Clinical Trials HeartWare International Inc. Medtronic Source Type: news
Stroke risk following implantation of current generation centrifugal flow left ventricular assist devices
ConclusionsDifferent LVAD models appear to be associated with significantly different stroke risks.
Source: Journal of Cardiac Surgery - December 5, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Yuting P. Chiang,
Daniel Cox,
Jacob N. Schroder,
Mani A. Daneshmand,
Laura J. Blue,
Chetan B. Patel,
Adam D. DeVore,
Muath Bishawi,
Carmelo A. Milano Tags: ORIGINAL ARTICLE Source Type: research
Pre-Operative Risk Factors of Bleeding and Stroke During Left Ventricular Assist Device Support An Analysis of More Than 900 HeartMate II Outpatients
ConclusionsThe risk of bleeding and thrombotic events during LVAD support differs by patient demographics, including sex, age, body mass index, and etiology of heart failure. Further studies should focus on the potential of tailored anticoagulation strategies in these subgroups.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - March 3, 2014 Category: Cardiology Source Type: research
FDA warns of high stroke, mortality risk with SynCardia TAH-t C2 controller
The FDA on Friday released a letter warning of a higher mortality risk and stroke rate than expected for patients receiving treatment from SynCardia Systems’ Temporary Total Artificial Heart Companion 2 Driver System.
Data indicating the higher mortality and stroke rate came from a post-approval study conducted by the company itself, the FDA said. The study indicated that patients treated with the previous generation driver of the device, the Circulatory Support System Console, experienced a lower rate of stroke and mortality compared with the C2.
The TAH-t system is designed to function as a bridge to a heart transplant...
Source: Mass Device - August 20, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Food & Drug Administration (FDA) SynCardia Source Type: news
Medtronic touts stroke data from HeartWare HVAD thoracotomy study
Medtronic (NYSE:MDT) today touted stroke data from the Lateral trial of its HeartWare HVAD left ventricular assist device involving implantation via thoracotomy instead of open surgery.
With a thoracotomy implantation, surgeons insert the pump via a small, lateral incision between the left ribs and make a second small incision to accommodate the pump’s outflow graft. Fridley, Minn.-based Medtronic said Lateral results presented at the annual meeting of the American Society for Artificial Internal Organs showed that 95% of thoractomy patients were free from disabling stroke at two years.
Adverse events were more like...
Source: Mass Device - July 8, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Assist Devices Cardiovascular Clinical Trials Featured Medtronic Source Type: news
Mechanical Circulatory Support Prior to Heart Transplantation Predicts Early Post-Operative Stroke
CONCLUSIONS: With the exception of left ventricular assist devices, use of MCS modalities leading to HT is significantly and independently associated with stroke during the early post-HT period.PMID:33785302 | DOI:10.1016/j.amjms.2021.03.008
Source: The American Journal of the Medical Sciences - March 31, 2021 Category: General Medicine Authors: Trenton J Bickel Prasad Gunasekaran Deepak K Parashara Martin A Alpert Source Type: research
